中文摘要：

目的探讨检测血清RNA中miR-221和miR-122在肝细胞癌患者血清中的表达及其临床意义。方法采用实时荧光定量逆转录-聚合酶链反应（reversetranscriotion—polymerasechainreaction，RT-PCR）对比检测72例肝细胞癌患者、48例肝良性疾病患者和60例正常对照组人员血清中miR-221和miR-122水平。分析miR-221和miR-122的表达程度与患者临床病理参数的关系。结果肝细胞癌患者血清miR-221和miR-122明显高于良性肝病和正常对照组（P〈0．05）。肝癌患者血清miR-221和miR-122表达的高低与肝硬化、甲胎蛋白、肿瘤大小、病理分化、临床病理TNM分级有关（P〈0．05）。结论血清miR-221和miR-122与肝癌的临床病理特征关系密切，可能是肝细胞癌新的早期检测指标。

英文摘要：

Objective To investigates the expression of miR-221 and miR-122 in serum of hepatocellular carcinoma （ HCC ） patients, as well as their clinical significance. Methods The blood samples were collected from 72 patients with HCC, 48 patients with benign disease and 60 normal subjects. The expression levels of miR-221and miR-122 in the serum were measured by reverse transcription polymerase chain reaction. The correlations of miR-221and miR-122 expression to the clinicopathologieal features were analyzed. Results HCC patients had significantly higher miR-221 and miR-122 levels than benign diseases and healthy controls. The expression level of serum miR-221 and miR-122 had a close correlation with liver cirrhosis, alpha fetoprotein level, tumor size, tumor thrombi, histological differentiation, tumor node metastasis classification （P 〈 0.05 ）. Conclusion The expression of miR-221 and miR-122 in serum had close correlations with the clinicopathologic features of hepatocellular carcinoma, indicating that miR-221 and miR-122 can be used as potential markers for HCC.